Worldwide Selects Medidata’s Payments Cloud for CRO Experience
NEW YORK – July 12, 2017 – Global provider of cloud-based technology and data analytics for clinical research, Medidata, announced that its Medidata Payments Cloud has been selected by Worldwide Clinical Trials (Worldwide) to streamline payments on behalf of their clinical trial sponsors.
Medidata Payments Cloud is a global site payment technology for the industry that’s driven by EDC. It focuses on studies across a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID), and rare diseases. Worldwide will leverage Medidata Payments Cloud to trigger, calculate, and disburse payments directly into an investigative site’s bank account, to benefit the CRO experience for sponsors and sites.
“Worldwide’s success as a CRO is down to our ability to partner successfully with our trial sponsors and sites – going above and beyond in the delivery, operation and support of all of our services,” said Anthony Doyle, Chief Financial Officer, Worldwide. “Medidata Payments Cloud stood out as a truly end-to-end solution, driven by EDC, and for the opportunity it provides us to reimburse sites as quickly and accurately as possible – important as we invest in processes and technology that help Worldwide continue to stand out as a top-ranked performer for service and customer loyalty.”
“Timeliness and accuracy in payments are critical to the success of contract research organizations, and achieving both can be incredibly challenging,” said April Mulroney, Managing Director of Payments at Medidata. “We’re proud that Worldwide has selected Medidata Cloud Payments, which will help them create an industry-leading site payment operation, ensuring sites are easily paid on time, and reporting to sponsors is accurate and timely.”
Medidata Contacts
Investor: Anthony D’Amico, +1 732-767-4331, adamico@mdsol.com
Media: Erik Snider, Medidata Solutions, +1 646-362-2997, esnider@mdsol.com
Worldwide Contacts
Media: Sherri Stuart, Worldwide Clinical Trials, +1 610-563-8768, sherri.stuart@worldwide.com
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
